PH26518A - A novel pharmaceutical composition comprising exifone and water-soluble polymer - Google Patents

A novel pharmaceutical composition comprising exifone and water-soluble polymer Download PDF

Info

Publication number: PH26518A
Authority: PH; Philippines
Prior art keywords: exifone; composition; water; soluble polymer; pharmaceutical composition
Prior art date: 1987-11-11

Application number

PH37783A

Other languages

English (en)

Inventor

Yoshio Ueda

Fumio Shinojo

Mitsuru Yasumura

Kenzo Toyoshina

Nobomitsu Nakahashi

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-11

Filing date

1988-11-09

Publication date

1992-08-07

1988-11-09 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

1992-08-07 Publication of PH26518A publication Critical patent/PH26518A/en

Links

XEDWWPGWIXPVRQ-UHFFFAOYSA-N (2,3,4-trihydroxyphenyl)-(3,4,5-trihydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC=C1C(=O)C1=CC(O)=C(O)C(O)=C1 XEDWWPGWIXPVRQ-UHFFFAOYSA-N 0.000 title claims abstract description 99
229950006404 exifone Drugs 0.000 title claims abstract description 99
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
229920003169 water-soluble polymer Polymers 0.000 title abstract description 29
239000000203 mixture Substances 0.000 claims description 111
239000007962 solid dispersion Substances 0.000 claims description 20
229920002678 cellulose Polymers 0.000 claims description 9
239000001913 cellulose Substances 0.000 claims description 9
238000013329 compounding Methods 0.000 claims description 6
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
239000006069 physical mixture Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 2
238000000034 method Methods 0.000 description 28
239000002775 capsule Substances 0.000 description 23
238000012360 testing method Methods 0.000 description 21
239000000126 substance Substances 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
238000009472 formulation Methods 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
239000011812 mixed powder Substances 0.000 description 13
238000007922 dissolution test Methods 0.000 description 12
238000004090 dissolution Methods 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
239000000654 additive Substances 0.000 description 9
239000003826 tablet Substances 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 8
-1 etc.) Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
230000000996 additive effect Effects 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
239000008187 granular material Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
230000036470 plasma concentration Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
241000282472 Canis lupus familiaris Species 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000005259 measurement Methods 0.000 description 6
229920000573 polyethylene Polymers 0.000 description 6
235000010980 cellulose Nutrition 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
238000004898 kneading Methods 0.000 description 5
238000002156 mixing Methods 0.000 description 5
238000010998 test method Methods 0.000 description 5
229920003114 HPC-L Polymers 0.000 description 4
239000007941 film coated tablet Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
241000894007 species Species 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 2
241001645982 Crax Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
101150003530 Tsnax gene Proteins 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000003801 milling Methods 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000005303 weighing Methods 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000007765 cera alba Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000013677 cerebrovascular dementia Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
XAEWZDYWZHIUCT-UHFFFAOYSA-N desipramine hydrochloride Chemical compound [H+].[Cl-].C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 XAEWZDYWZHIUCT-UHFFFAOYSA-N 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
239000012907 medicinal substance Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007873 sieving Methods 0.000 description 1
DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000012085 test solution Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)

PH37783A 1987-11-11 1988-11-09 A novel pharmaceutical composition comprising exifone and water-soluble polymer PH26518A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP28449387		1987-11-11

Publications (1)

Publication Number	Publication Date
PH26518A true PH26518A (en)	1992-08-07

Family

ID=17679231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH37783A PH26518A (en)	1987-11-11	1988-11-09	A novel pharmaceutical composition comprising exifone and water-soluble polymer

Country Status (8)

Country	Link
US (1)	US5093372A (fr)
EP (1)	EP0315964B1 (fr)
KR (1)	KR0132571B1 (fr)
AT (1)	ATE84213T1 (fr)
CA (1)	CA1319110C (fr)
DE (1)	DE3877331T2 (fr)
ES (1)	ES2043766T3 (fr)
PH (1)	PH26518A (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2640137A1 (fr) *	1988-12-08	1990-06-15	Texinfine Sa	Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
DK0489181T3 (da) *	1990-07-19	1996-11-18	Otsuka Pharma Co Ltd	Fast præparat
US5977077A (en) *	1995-08-28	1999-11-02	Interlab Corporation	Xanthone analogs for the treatment of infectious diseases
US6645988B2 (en)	1996-01-04	2003-11-11	Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en)	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
WO1998019708A2 (fr) *	1996-11-04	1998-05-14	Union Carbide Chemicals & Plastics Technology Corporation	Procede pour ameliorer la solubilite de composes sensiblement insolubles dans l'eau
TW486370B (en) *	1996-12-25	2002-05-11	Yamanouchi Pharma Co Ltd	Rapidly disintegrable pharmaceutical composition
AU763143B2 (en)	1998-04-08	2003-07-17	Kyowa Hakko Kirin Co., Ltd.	Tablet manufacturing method and tablet
US6613797B2 (en)	1999-12-02	2003-09-02	Interlab, Inc.	Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins
CN1402629A (zh)	1999-12-23	2003-03-12	辉瑞产品公司	提供提高的药物浓度的药物组合物
CA2450748A1 (fr) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Compositions pharmaceutiques contenant des ensembles polymere et medicament
EP1269994A3 (fr) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
AU2003301121A1 (en) *	2002-12-18	2004-07-14	Pain Therapeutics, Inc.	Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5212114B2 (ja) *	2007-01-31	2013-06-19	旭硝子株式会社	塩化アルカリ電解用イオン交換膜
CN106138018B (zh)	2015-04-02	2020-03-13	广州洁成生物科技有限公司	羟基二苯甲酮在制备抗病毒和抗肿瘤药物中的应用
KR20180101404A (ko) *	2015-12-17	2018-09-12	메사추세츠 인스티튜트 오브 테크놀로지	폴리히드록실화된 벤조페논의 조성물 및 신경변성 장애의 치료 방법
JP7074677B2 (ja) *	2016-02-16	2022-05-24	シガ・テクノロジーズ・インコーポレーテッド	Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤
US11517548B2 (en) *	2018-07-19	2022-12-06	Impel Pharmaceuticals Inc.	Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1492034A1 (de) *	1965-05-18	1969-02-20	Merck Ag E	Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
JPS5439445B2 (fr) *	1973-03-24	1979-11-28
FR2257272B1 (fr) *	1974-01-15	1978-08-25	Pharmascience Labo
FR2377202A2 (fr) *	1977-01-12	1978-08-11	Pharmascience Lab	Compositions pharmaceutiques contenant de l'hexahydroxy-2,3,4,3',4',5'-benzophenone
GB1579818A (en) *	1977-06-07	1980-11-26	Yamanouchi Pharma Co Ltd	Nifedipine-containing solid preparation composition
US4145440A (en) *	1977-08-18	1979-03-20	The Upjohn Company	Liquid suspension of an aluminum salt of ibuprofen
JPS6038322A (ja) *	1983-08-11	1985-02-27	Fujisawa Pharmaceut Co Ltd	ジヒドロピリジンａ物質含有易溶性固形製剤
GB8608080D0 (en) *	1986-04-02	1986-05-08	Fujisawa Pharmaceutical Co	Solid dispersion composition

1988
- 1988-11-09 EP EP88118627A patent/EP0315964B1/fr not_active Expired - Lifetime
- 1988-11-09 AT AT88118627T patent/ATE84213T1/de not_active IP Right Cessation
- 1988-11-09 ES ES88118627T patent/ES2043766T3/es not_active Expired - Lifetime
- 1988-11-09 DE DE8888118627T patent/DE3877331T2/de not_active Expired - Fee Related
- 1988-11-09 PH PH37783A patent/PH26518A/en unknown
- 1988-11-10 CA CA000582787A patent/CA1319110C/fr not_active Expired - Fee Related
- 1988-11-10 KR KR1019880014768A patent/KR0132571B1/ko not_active Expired - Fee Related
1990
- 1990-03-02 US US07/488,492 patent/US5093372A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE3877331T2 (de)	1993-05-27
US5093372A (en)	1992-03-03
CA1319110C (fr)	1993-06-15
DE3877331D1 (de)	1993-02-18
ATE84213T1 (de)	1993-01-15
KR890007722A (ko)	1989-07-05
EP0315964A1 (fr)	1989-05-17
KR0132571B1 (ko)	1998-04-17
ES2043766T3 (es)	1994-01-01
EP0315964B1 (fr)	1993-01-07

Publication	Publication Date	Title
US5093372A (en)	1992-03-03	Novel pharmaceutical composition comprising exifone and water-soluble polymer
DE69905380T2 (de)	2003-11-27	Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
DE3783394T2 (de)	1993-05-06	Arzneizubereitung zur oralen anwendung.
CA1125656A (fr)	1982-06-15	Produit pharmaceutique en comprimes pour administration par voie orale et procede de production
EP0120118A1 (fr)	1984-10-03	Formulations solides de médicaments cardiovasculaires à libération constante administrables par voie orale
JPS6124516A (ja)	1986-02-03	持続性錠剤
US5968553A (en)	1999-10-19	Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
WO2000064416A2 (fr)	2000-11-02	Formulation pharmaceutique
US12257347B2 (en)	2025-03-25	Pharmaceutical composition comprising meta arsenite and method of manufacture
EP0425298A2 (fr)	1991-05-02	Préparation À libération retardée d'un chlorhydrate d'un médicament basique
EP3419605B1 (fr)	2026-04-08	Formulation de dasatinib
SK283249B6 (sk)	2003-04-01	Tableta vyrobiteľná priamym tabletovaním, obsahujúca aktívnu látku kyselinu 4-amino-1-hydroxybutylidén-1,1-bisfosfónovú a spôsob jej výroby
RU2236231C2 (ru)	2004-09-20	Таблетка циклофосфамида с пленочным покрытием (варианты) и способ ее получения, ядро таблетки и способ его получения
EP2101742B1 (fr)	2011-05-11	Composition pharmaceutique contenant de l'hydrogénosulfate de clopidogrel de forme polymorphe 1
US4521402A (en)	1985-06-04	Constant release rate solid oral dosage formulations of hydrazine
JPS62123117A (ja)	1987-06-04	塩酸ニカルジピン経口用組成物
JP2591235B2 (ja)	1997-03-19	アルキルシステインまたはその酸付加塩を含有する安定な錠剤
JPH02206A (ja)	1990-01-05	エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
US6136833A (en)	2000-10-24	Pharmaceutical formulations and process for their preparation
CA2499149A1 (fr)	2004-04-01	Formulation de mannitol destinee a un antagoniste de recepteur d'integrine
JPS6242918A (ja)	1987-02-24	持続性製剤
CN118986976B (zh)	2025-04-15	吡啶并咪唑硫代丙酸化合物晶型Form13的药物组合物及其片剂的制备方法
EP0974343B1 (fr)	2004-09-29	Procédé de préparation d'une composition solide contentant du metoprolol
WO2002011726A1 (fr)	2002-02-14	Preparation solide hautement absorbable
CN121774903A (zh)	2026-04-03	一种艾普拉唑肠溶片及其制备方法